Alternate Name(s):
SUFENTA®
Classification:
Narcotic analgesic
Original Date:
August 2005
Indications:
- Induction and maintenance of anesthesia (with 100% oxygen)
- Analgesic adjunct
Reconstitution and Stability:
- Available as a 50 mcg/mL injection
- Store at room temperature. Protect from light
Compatibility:
- Solutions Compatible: D5W, NS
- Y-site Compatible: propofol
- Incompatible: acidic solutions, thiopental
Administration:
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
| SC | NO |
| IM | NO |
| IV Push |
YES |
| IV Intermittent Infusion | YES Usual dilution: dilute in D5W or NS Infusion rate: >1 mcg/kg/hr in children >12 years |
| IV Continuous Infusion | YES: in NICU |
Dosage:
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
- Titrate dose to appropriate effects; wide range of doses dependant upon desired degree of analgesia or anesthesia
Children 2-12 years:
- Anesthesia:
- Initial: 10-25 mcg/kg IV
- Maintenance: up to 25-50 mcg IV PRN
Adult:
- Anesthesia:
- Initial: 8-30 mcg/kg IV
- Maintenance: 10-50 mcg IV PRN
- Analgesic Adjunct:
- Low Dose:
- Initial: 0.5-1 mcg/kg IV
- Maintenance: 10-25 mcg IV PRN - Moderate Dose:
- Initial: 2-8 mcg/kg IV
- Maintenance: 10-50 mcg IV PRN
Potential hazards of parenteral administration:
- Apnea, respiratory depression
- Hypotension, hypertension, bradycardia
- CNS depression, sedation, dizziness
- Nausea, vomiting
- Skeletal muscle and chest wall rigidity (especially with rapid IV administration)
- Antidote: Naloxone
Notes:
- Contraindicated in increased intracranial pressure and severe respiratory depression
- Monitor respiratory rate, blood pressure, heart rate, oxygen saturation, neurological status (degree of analgesia/anesthesia)
- Abrupt discontinuation after prolonged use may result in withdrawal symptoms
- Onset of action: 1-3 minutes
- Duration: dose dependant
- Anesthesia adjunct doses: 5 minutes